UNSPSC 51143712: Niacin/pentylenetetrazol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

UNSPSC 51143712 Niacin/pentylenetetrazol is a Commodity code, but recent state and local procurement activity under this code does not align with its nominal scope. The three most recent opportunities posted in 2026 involve naloxone and drug deactivation systems (Seminole County, Florida), therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference niacin or pentylenetetrazol; the code appears to have been applied to pharmaceutical procurement opportunities more broadly, suggesting either a classification mismatch or a drift in how jurisdictions tag pharmaceutical and health-service purchases under this taxonomy entry.

The issuing bodies include county health agencies (Seminole County), state health and human services departments (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP serving Minnesota, Oregon, and other participants). Geographic activity is concentrated in the South and Midwest, with recent notices from Florida, Texas, and Minnesota. The Seminole County procurement (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB with quarterly deliveries; the Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription programs; and MMCAP's RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson). The code shows limited relevant recent activity tied to its stated pharmaceutical scope.